Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

ALNYLAN Form 4 August 16,	/I PHARMACEU [*] 2013	TICALS, I	NC.									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB AF OMB Number:	-		
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Expires: January 31, 2005 Estimated average burden hours per response 0.5				
(Print or Type	Responses)											
MARAGANORE JOHN Sy Al Ph			Symbol ALNY	ymbol ILNYLAM HARMACEUTICALS, INC.					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner			
()				Date of Earliest Transaction					X_Officer (give titleOther (specify below) below) Chief Executive Officer			
CAMBRII	(Street) DGE, MA 02142		4. If Am Filed(Mo			ate Origina r)	ıl	A 	. Individual or Joi applicable Line) X_ Form filed by Ou Form filed by Mo erson	ne Reporting Per	rson	
(City)	(State)	(Zip)	Tab	ole I - N	on-]	Derivative	Secu		red, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deeme Execution I any (Month/Da	ned 3. 4. See n Date, if Transactionor Di Code (Instr Day/Year) (Instr. 8)			nor Dispos (Instr. 3, 4	ed of (and f (A) or	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	08/14/2013			Code $M^{(1)}$	v	Amount 60,000	(D) A	Price \$ 0.95	78,617	D		
Common Stock	08/14/2013			S <u>(1)</u>		19,763	D	\$ 48.7749 (2)	58,854	D		
Common Stock	08/14/2013			S <u>(1)</u>		40,237	D	\$ 49.064 (3)	18,617	D		
Common									2,605	I	By	

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

Stock									$\begin{array}{c} \text{Managed} \\ \text{Account} \\ \underline{^{(4)}} \end{array}$	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information contained in this form are not information contained in this form are not information contained to respond unless the form displays a currently valid OMB control number. (9-02) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned										
(<i>e.g.</i> , puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of ionDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 0.95	08/14/2013		M <u>(1)</u>		60,000	(5)	01/06/2014 <u>(1)</u>	Common Stock	60,000
Reporting Owners										

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
MARAGANORE JOHN C/O ALNYLAM PHARMACEUTICALS, INC. 300 THIRD STREET CAMBRIDGE, MA 02142	Х		Chief Executive Officer					
Signatures								
/s/ Michael P. Mason, Attorney-in-Fact for John Maraganore	M.	(08/16/2013					
** Signature of Reporting Person			Date					
Explanation of Pospansos:								

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2012. The options exercised and sold by the reporting person were due to expire on January 6, 2014.

Edgar Filing: ALNYLAM PHARMACEUTICALS, INC. - Form 4

- (2) Sale prices ranged from \$47.95 to \$48.94.
- (3) Sale prices ranged from \$48.95 to \$49.39.
- (4) The reporting person owns 2,605 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- (5) The stock option vested upon the closing of the initial public offering of common stock by the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.